HC Wainwright Has Negative Outlook for Geron FY2028 Earnings

Geron Co. (NASDAQ:GERN) – Analysts at HC Wainwright dropped their FY2028 earnings per share estimates for Geron in a research note issued to investors on Wednesday, May 7th. HC Wainwright analyst E. Bodnar now forecasts that the biopharmaceutical company will post earnings per share of $0.21 for the year, down from their prior estimate of $0.30. HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Geron’s current full-year earnings is ($0.25) per share. HC Wainwright also issued estimates for Geron’s FY2029 earnings at $0.49 EPS.

Geron (NASDAQ:GERN) last announced its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported ($0.03) EPS for the quarter, beating the consensus estimate of ($0.04) by $0.01. The firm had revenue of $39.60 million during the quarter, compared to analyst estimates of $49.88 million. Geron had a negative net margin of 682.48% and a negative return on equity of 67.53%. Geron’s revenue was up 12927.3% on a year-over-year basis. During the same period last year, the firm posted ($0.07) EPS.

Several other equities analysts also recently issued reports on the company. Barclays reissued an “overweight” rating and issued a $4.00 target price (down from $9.00) on shares of Geron in a research report on Thursday, February 27th. Scotiabank cut Geron from a “sector outperform” rating to a “sector perform” rating and reduced their price objective for the stock from $4.00 to $1.50 in a research note on Thursday. Stifel Nicolaus decreased their target price on Geron from $8.00 to $4.00 and set a “buy” rating for the company in a report on Thursday, February 27th. B. Riley downgraded shares of Geron from a “buy” rating to a “neutral” rating and cut their price target for the stock from $3.50 to $2.00 in a report on Thursday, February 27th. Finally, Needham & Company LLC restated a “buy” rating and set a $5.00 price objective on shares of Geron in a research note on Wednesday, March 12th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $5.06.

Geron Trading Down 6.0 %

NASDAQ GERN opened at $1.19 on Friday. Geron has a 12-month low of $1.17 and a 12-month high of $5.34. The company has a fifty day simple moving average of $1.49 and a two-hundred day simple moving average of $2.73. The company has a current ratio of 2.89, a quick ratio of 2.74 and a debt-to-equity ratio of 0.04. The stock has a market cap of $754.74 million, a P/E ratio of -3.70 and a beta of 0.76.

Institutional Investors Weigh In On Geron

Hedge funds and other institutional investors have recently made changes to their positions in the company. Barclays PLC boosted its holdings in Geron by 114.9% during the third quarter. Barclays PLC now owns 1,299,912 shares of the biopharmaceutical company’s stock worth $5,902,000 after buying an additional 694,931 shares in the last quarter. Moody National Bank Trust Division raised its position in shares of Geron by 76.6% in the fourth quarter. Moody National Bank Trust Division now owns 267,629 shares of the biopharmaceutical company’s stock worth $947,000 after acquiring an additional 116,074 shares during the period. Elmwood Wealth Management Inc. purchased a new stake in shares of Geron during the 4th quarter worth about $93,000. Rovin Capital UT ADV grew its position in shares of Geron by 26.9% during the 4th quarter. Rovin Capital UT ADV now owns 17,270 shares of the biopharmaceutical company’s stock valued at $61,000 after acquiring an additional 3,660 shares during the period. Finally, Hennion & Walsh Asset Management Inc. increased its stake in shares of Geron by 18.1% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 403,703 shares of the biopharmaceutical company’s stock valued at $1,429,000 after purchasing an additional 61,819 shares in the last quarter. Institutional investors and hedge funds own 73.71% of the company’s stock.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.